While the annual meeting of the European Society for Medical Oncology (ESMO) of course mainly focusses on advances in solid tumours, this year’s edition also featured a session zooming on haematological malignancies. In this session, encouraging results were presented for the combination of lemzoparlimab, a CD47 antibody, with azacytidine, in the treatment of patients with myelodysplastic syndromes. In addition, also the new anti-CD20-MMAE antibody-drug conjugate TRS005 displayed promising activity in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Finally, two interesting studies were presented using novel CAR-T constructs, one CAR-T expressing a PD1 knock-down gene for the treatment of CD19+ B cell malignancies, and a second CAR-T construct targeting BCMA, for the treatment of R/R myeloma.

(BELG J HEMATOL 2022;13(8):333–6)